Why is NeurAxis, Inc. ?
Unrated Stock - No Analysis Available
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
No Data Found
Quality key factors
Factor
Value
Sales Growth (5y)
15.01%
EBIT Growth (5y)
-13.93%
EBIT to Interest (avg)
-3.65
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.86
Sales to Capital Employed (avg)
-0.39
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
16.04%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
32.87
EV to EBIT
-9.37
EV to EBITDA
-9.42
EV to Capital Employed
-38.71
EV to Sales
21.11
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-330.30%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Dow Theory
No Trend
Bullish
OBV
Mildly Bullish
Mildly Bullish
Technical Movement
8What is working for the Company
NET SALES(HY)
At USD 1.71 MM has Grown at 33.44%
NET PROFIT(HY)
Higher at USD -3.81 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 41.74 times
-4What is not working for the Company
ROCE(HY)
Lowest at -3,071.15%
Here's what is working for NeurAxis, Inc.
Net Sales
At USD 1.71 MM has Grown at 33.44%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Profit
Higher at USD -3.81 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 41.74 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio






